| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EURURO.2011.06.035 |
| P698 | PubMed publication ID | 21719191 |
| P50 | author | Shahrokh Shariat | Q7462263 |
| P2093 | author name string | Rui Henrique | |
| Giuseppina M Carbone | |||
| Susan J Clark | |||
| Carmen Jerónimo | |||
| James W F Catto | |||
| William G Nelson | |||
| Anders Bjartell | |||
| Patrick J Bastian | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | epigenetics | Q26939 |
| prostate cancer | Q181257 | ||
| P304 | page(s) | 753-766 | |
| P577 | publication date | 2011-06-22 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Epigenetics in prostate cancer: biologic and clinical relevance | |
| P478 | volume | 60 |
| Q38074010 | Aberrant PSA glycosylation--a sweet predictor of prostate cancer. |
| Q37597723 | Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes. |
| Q38998403 | Anti-neoplastic properties of hydralazine in prostate cancer |
| Q28085136 | Artificial light at night: melatonin as a mediator between the environment and epigenome |
| Q48007156 | Association of epigenetic alterations in the human C7orf24 gene with the aberrant gene expression in malignant cells |
| Q37474443 | Biomarkers for prostate cancer: present challenges and future opportunities |
| Q37148139 | Biomarkers in prostate cancer epidemiology |
| Q64089584 | Can Lycopene Impact the Androgen Axis in Prostate Cancer?: A Systematic Review of Cell Culture and Animal Studies |
| Q35903128 | Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice |
| Q28817152 | Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection |
| Q26776038 | Cracking the Code of Human Diseases Using Next-Generation Sequencing: Applications, Challenges, and Perspectives |
| Q35140145 | Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer |
| Q38913306 | DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer |
| Q38833395 | DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects. |
| Q90162252 | DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types |
| Q36190050 | DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells |
| Q38642046 | DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. |
| Q42676794 | DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy |
| Q39025282 | Deregulation of an imprinted gene network in prostate cancer |
| Q37972703 | Diagnostic and prognostic molecular biomarkers for prostate cancer |
| Q26991774 | Dietary factors and epigenetic regulation for prostate cancer prevention |
| Q37506007 | Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells |
| Q42268071 | Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis. |
| Q39156176 | Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing. |
| Q36187865 | Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion |
| Q39380271 | Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma |
| Q47563953 | Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients |
| Q36286662 | Epigenetic mechanisms in commonly occurring cancers. |
| Q28071912 | Epigenetic modulators as therapeutic targets in prostate cancer |
| Q38957460 | Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential |
| Q39042632 | Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer |
| Q37707110 | Epigenetic therapy in urologic cancers: an update on clinical trials. |
| Q40674443 | Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer |
| Q37055783 | Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue |
| Q27323950 | Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors |
| Q39346439 | Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence |
| Q37632337 | Extracellular vesicles in prostate cancer: new future clinical strategies? |
| Q37993339 | Feedback networks between microRNAs and epigenetic modifications in urological tumors. |
| Q39026460 | Functional links between Snail-1 and Cx43 account for the recruitment of Cx43-positive cells into the invasive front of prostate cancer |
| Q40356316 | Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer |
| Q37139054 | Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. |
| Q57106917 | Genetics and biology of prostate cancer |
| Q38266607 | Global DNA hypomethylation in prostate cancer development and progression: a systematic review |
| Q41122284 | Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. |
| Q40356065 | High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer |
| Q41811530 | Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer |
| Q64932707 | Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype. |
| Q50098159 | Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression. |
| Q39056710 | Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression |
| Q38537765 | KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease |
| Q37662226 | MIEN1 is tightly regulated by SINE Alu methylation in its promoter |
| Q35875365 | Male reproductive health and prostate cancer risk |
| Q47215343 | Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer |
| Q39155363 | Meta-analyses of methylation markers for prostate cancer |
| Q38740526 | Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells |
| Q35678056 | Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer |
| Q34847101 | Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer |
| Q40985522 | Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. |
| Q35606022 | MicroRNA-375 plays a dual role in prostate carcinogenesis |
| Q36596346 | MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer |
| Q38011943 | MicroRNAs as putative mediators of treatment response in prostate cancer |
| Q33625338 | Novel tools for prostate cancer prognosis, diagnosis, and follow-up |
| Q26740548 | One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling |
| Q50866916 | P16 hypermethylation predicts surgical outcome following curative resection of mid/distal bile duct cancer. |
| Q64326514 | Potential Epigenetic Biomarkers for Prostate Cancer Screening |
| Q38644658 | Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications |
| Q58554204 | Promising Antineoplastic Actions of Melatonin |
| Q42359959 | Prostate Cancer Patients-Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics |
| Q38212471 | Prostate cancer epigenetic biomarkers: next-generation technologies. |
| Q38271076 | Prostate cancer epigenome |
| Q30414232 | Prostate cancer induced by loss of Apc is restrained by TGFβ signaling |
| Q42036127 | Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth |
| Q39078249 | Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer. |
| Q38380233 | Regulation of miR-200c and miR-141 by Methylation in Prostate Cancer |
| Q64112125 | Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe-Dnmts axis |
| Q34039935 | TGF-β mediated DNA methylation in prostate cancer |
| Q38160734 | The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer |
| Q39351158 | The SNP rs6441224 influences transcriptional activity and prognostically relevant hypermethylation of RARRES1 in prostate cancer |
| Q39397231 | The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression |
| Q44538170 | The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies |
| Q21245762 | The emerging role of histone lysine demethylases in prostate cancer |
| Q38161941 | The epigenetic potentials of dietary polyphenols in prostate cancer management |
| Q36925266 | The genetics of neuroendocrine prostate cancers: a review of current and emerging candidates |
| Q36390674 | The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer |
| Q26851631 | The mutational landscape of prostate cancer |
| Q37986402 | The role of connexins in prostate cancer promotion and progression |
| Q34227747 | The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth |
| Q36361936 | Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol |
| Q64260465 | Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells |
| Q28069898 | Tumour biomarkers: homeostasis as a novel prognostic indicator |
| Q64296840 | UNC5D, suppressed by promoter hypermethylation, inhibits cell metastasis by activating death-associated protein kinase 1 in prostate cancer |
| Q28269116 | Wnt/β-catenin signalling in prostate cancer |
| Q35794952 | miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer. |
| Q39214638 | miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men. |
Search more.